Shots: Obsidian to receive $75M in equity, up front, research milestones and is eligible to receive ~$1.3B as research, development, regulatory, and commercial milestones across up to five potential programs. Additionally, Obsidian will receive royalties on sales of products that emerge from the collaboration Obsidian will deploy its cytoDRiVE platform to discover controllable genetic therapies […]Read More
Shots: Anima to receive ~ $120M up front, preclinical milestones and ~$1.1B as clinical and commercial milestones along with royalties on each product emerge under the collaboration Takeda gets an exclusive right to develop and commercialize the mRNA transational modulators and has a time limited option to expands the collaboration for three additional targets for […]Read More
Shots: SMA Foundation and PTC will provide an initial investment of up to $60M in research to discover & develop regenerative treatments in neuromuscular diseases The focus of the agreement is advance scientific research in SMA and other neuromuscular disorders to develop new treatments The availability of several disease-modifying therapies has made regenerative interventions the […]Read More
Shots: Biolojic to receive ~$121M including development and commercialization milestones and a promissory note that may be convertible into Biolojic equity in future Additionally, Biolojic is eligible to receive royalties on sales of therapies that emerges during the collaboration The collaboration will leverage Biolojic’s AI-based multibody platform to discover and develop a potential novel Ab-based […]Read More
Shots: The Gates Foundation will provide funding support to discover and develop in vivo gene therapy for SCD. The alliance brings together Novartis drug discovery and gene therapy expertise with Gates’ funding’s The focus of the agreement to address the disparity in access to treatments and to prioritize populations and regions bearing the greatest burden […]Read More
Shots: MTEM to receive $70M up front and is also eligible to receive ~$1.3B as development, regulatory, and sales milestone along with royalties on future sales MTEM will be responsible for research activities to discover next-generation ETBs for multiple targets, of which BMS selected the first target. BMS to get an option to obtain an […]Read More
Shots: Merus to receive $40M up front, $20M as an equity investment, ~$540M as development & commercial milestones making it a total of $1.6B for three products, along with royalties, following the commercialization of therapies Merus will lead discovery and early-stage research activities while Loxo Oncology at Lilly will be responsible for additional research, development, […]Read More
Shots: Skyhawk to receive $40M as upfront and is eligible to receive up to $2.2B as milestones along with royalties on sales. Vertex to get an option to exclusively license WW IP rights to candidates discovered and developed under the collaboration directed at serious diseases Following the exercise of its options, Vertex will be responsible […]Read More
Shots: Frontier to receive$55M up front and is eligible for development & commercial milestone that could exceed $1B, along with royalties on commercialized products. The company might get ~45M within the first 12mos. of collaboration Following the completion of pre-clinical development, AbbVie will lead global development and commercialization activities and costs for the programs whereas […]Read More
Shots: The companies entered into an exclusive research agreement for the discovery of novel small molecules targeting α-synuclein for the potential treatment of synucleinopathies including PD and dementia with Lewy bodies The collaboration will use Wren’s network kinetics drug discovery platform along with Eisai’s experience in drug discovery for neurodegenerative disorders, to accelerate the development […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
